The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | How will JAK inhibitors fit into the NSCLC treatment landscape?
Melina Marmarelis, MD, University of Pennsylvania, Philadelphia, PA, comments on the emerging role of JAK inhibitors in the treatment of non-small cell lung cancer (NSCLC). Patients who have progressed on immunotherapy will benefit from JAK inhibitors, where they can further stimulate and support the immune system. Further studies will assess their efficacy in this setting. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
